Abstract
Diagnosis and therapy of bronchogenic carcinoma has recently undergone a number of major changes. In the field of diagnostics new WHO morphological classification of lung tumors came into force and new TNM classification also has been comming into practice.
Pulmonary carcinoma therapy still remains on the three pillars - surgical treatment, radiotherapy and systemic therapy. Surgery and radiotherapy bring about shifts in techniques that, due to greater precision and lesser side effects, can make these modalities available to patients where this treatment would not have been possible earlier and would thus be able to significantly prolong survival to the patients.
The whole treatment then underwent a radical change when new treatment options emerged. Whether it is targeted chemotherapy according to the morphological type of tumor, targeted drugs for EGFR mutations, ALK and ROS1 translocation, biological and targeted therapy directed to vasculogenesis, as well as newly emerging immunotherapy options, which are also beginning to appear in the first line of treatment in selected patients.